EP3976014A4 - A combination comprising alogliptin and metformin - Google Patents

A combination comprising alogliptin and metformin Download PDF

Info

Publication number
EP3976014A4
EP3976014A4 EP20815329.6A EP20815329A EP3976014A4 EP 3976014 A4 EP3976014 A4 EP 3976014A4 EP 20815329 A EP20815329 A EP 20815329A EP 3976014 A4 EP3976014 A4 EP 3976014A4
Authority
EP
European Patent Office
Prior art keywords
alogliptin
metformin
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20815329.6A
Other languages
German (de)
French (fr)
Other versions
EP3976014A1 (en
Inventor
Gulcin TOK
Ediz Yildirim
Ali Turkyilmaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3976014A1 publication Critical patent/EP3976014A1/en
Publication of EP3976014A4 publication Critical patent/EP3976014A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP20815329.6A 2019-05-24 2020-04-15 A combination comprising alogliptin and metformin Pending EP3976014A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2019/07905A TR201907905A1 (en) 2019-05-24 2019-05-24 A COMBINATION WITH ALOGLIPTIN AND METFORMIN
PCT/TR2020/050317 WO2020242413A1 (en) 2019-05-24 2020-04-15 A combination comprising alogliptin and metformin

Publications (2)

Publication Number Publication Date
EP3976014A1 EP3976014A1 (en) 2022-04-06
EP3976014A4 true EP3976014A4 (en) 2023-02-15

Family

ID=73553852

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20815329.6A Pending EP3976014A4 (en) 2019-05-24 2020-04-15 A combination comprising alogliptin and metformin

Country Status (3)

Country Link
EP (1) EP3976014A4 (en)
TR (1) TR201907905A1 (en)
WO (1) WO2020242413A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR202022144A1 (en) * 2020-12-29 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL COMPOSITIONS CONTAINING ALOGLIPTINE
CN113081973A (en) * 2021-05-07 2021-07-09 郑州泰丰制药有限公司 Metformin hydrochloride composition and preparation method thereof
KR20230051096A (en) * 2021-10-08 2023-04-17 (주)셀트리온 Pharmaceutical composition for treatment of diabetes with improved stability

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011451A1 (en) * 2007-07-19 2009-01-22 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
KR20150059166A (en) * 2015-05-12 2015-05-29 씨제이헬스케어 주식회사 Pharmaceutical combination comprising sustained-release type metformin and immediate-release type HMG-CoA reductase inhibitor
WO2017033115A1 (en) * 2015-08-21 2017-03-02 Alembic Pharmaceuticals Limited Stable pharmaceutical composition of alogliptin and metformin fixed dose combination
US20180235966A1 (en) * 2015-08-20 2018-08-23 Torrent Pharmaceuticals Limited Pharmaceutical composition of alogliptin and metformin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071175A1 (en) * 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
WO2013179307A2 (en) 2012-05-29 2013-12-05 Mylan Laboratories Limited Stabilized pharmaceutical compositions of saxagliptin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011451A1 (en) * 2007-07-19 2009-01-22 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
KR20150059166A (en) * 2015-05-12 2015-05-29 씨제이헬스케어 주식회사 Pharmaceutical combination comprising sustained-release type metformin and immediate-release type HMG-CoA reductase inhibitor
US20180235966A1 (en) * 2015-08-20 2018-08-23 Torrent Pharmaceuticals Limited Pharmaceutical composition of alogliptin and metformin
WO2017033115A1 (en) * 2015-08-21 2017-03-02 Alembic Pharmaceuticals Limited Stable pharmaceutical composition of alogliptin and metformin fixed dose combination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020242413A1 *

Also Published As

Publication number Publication date
TR201907905A1 (en) 2020-12-21
WO2020242413A1 (en) 2020-12-03
EP3976014A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
EP3917526A4 (en) Compounds and uses thereof
EP3917934A4 (en) Compounds and uses thereof
EP4076448A4 (en) Fluoroalkyl-oxadiazoles and uses thereof
EP3917517A4 (en) Compounds and uses thereof
EP3917529A4 (en) Compounds and uses thereof
EP3976014A4 (en) A combination comprising alogliptin and metformin
EP3917527A4 (en) Compounds and uses thereof
EP4055934A4 (en) Reference signaling design and configuration
EP3847011A4 (en) A lamitube and implementations thereof
EP3745873A4 (en) Protecting a bioactive and/or precursor thereof
EP4011898A4 (en) 3-hydroxy-5-pregnane-20-one derivative and use thereof
EP3731837A4 (en) The combination comprising linagliptin and metformin
EP4082614A4 (en) Acylsulfamide compound and pharmaceutical use therefor
EP4049159A4 (en) Ransomware prevention
EP4025194A4 (en) A combination comprising vildagliptin and metformin
EP3927779A4 (en) Antimicrobial azo compounds and uses thereof
EP3914593A4 (en) Compounds and uses thereof
EP3911322A4 (en) Compounds and uses thereof
IL290003A (en) A tissue-adhesive matrix and uses thereof
EP4051270A4 (en) 4-amino-imidazoquinoline compounds and use thereof
EP3983094A4 (en) A connection arrangement for a trampoline and a trampoline
IL289602A (en) A composition, a kit and use thereof
EP4004015A4 (en) A teixobactin analogue and use thereof
EP4031179A4 (en) Pharmaceutical combination and use thereof
EP4051669A4 (en) Ssao inhibitors and use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230116

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/30 19900101ALI20230110BHEP

Ipc: A61K 9/48 19740701ALI20230110BHEP

Ipc: A61K 9/20 19740701ALI20230110BHEP

Ipc: A61K 31/513 20000101ALI20230110BHEP

Ipc: A61K 31/155 19740701AFI20230110BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708